A process for production of malic acid includes obtaining a feed that includes one or more of crude maleic anhydride, pure maleic anhydride, crude maleic acid, crude fumaric acid, pure maleic acid, pure fumaric acid, vent gas scrubber solutions from production of maleic anhydride, and vent gas scrubber solutions from production of phthalic anhydride. The feed is passed in a tubular reactor assembly to obtain a first product stream, which includes unreacted feed and malic acid. The feed is made to undergo hydration reaction in the tubular reactor assembly for a first predetermined time period, and further hydration of the first product stream is caused in a stirred tank reactor assembly for a second predetermined time period to obtain a final product stream, which includes the malic acid.

A process for production of malic acid includes obtaining a feed that includes one or more of crude maleic anhydride, pure maleic anhydride, crude maleic acid, crude fumaric acid, pure maleic acid, pure fumaric acid, vent gas scrubber solutions from production of maleic anhydride, and vent gas scrubber solutions from production of phthalic anhydride. The feed is passed in a tubular reactor assembly to obtain a first product stream, which includes unreacted feed and malic acid. The feed is made to undergo hydration reaction in the tubular reactor assembly for a first predetermined time period, and further hydration of the first product stream is caused in a stirred tank reactor assembly for a second predetermined time period to obtain a final product stream, which includes the malic acid.

Provided are a salt form and a crystal form of adenosine A.sub.2A receptor antagonist, and preparation method therefor. Also provided is an application of the salt form or crystal form in the preparation of a medicine for A.sub.2A receptor-related diseases, the maleate salt in the salt form has a structure of formula (I).

##STR00001##

The present invention relates to a salt of 5-((2-ethynyl-5-isopropylpyridin-4-yl)oxy)pyrimidine-2,4-diamine and a solid form thereof, a method for preparing the solid form and a pharmaceutical composition comprising the solid form, as well as a use of the solid form for preventing or treating diseases modulated by P2X3 and/or P2X2/3 receptor antagonists.

Disclosed herein are a crystalline or amorphous form of a Bcl-2/Bcl-xL inhibitor compound or a salt thereof, and a preparation method and application thereof.

Disclosed herein are a crystalline or amorphous form of a Bcl-2/Bcl-xL inhibitor compound or a salt thereof, and a preparation method and application thereof.

The present invention is directed to stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydrofolic acid or a pharmaceutically acceptable salt thereof and a dicarboxylic acid, or a salt thereof, as well as, a processes of obtaining the same, and the use of such products.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

Provided are a crystal form of a maleate of a tyrosine kinase inhibitor and a preparation method therefor. Specifically, provided are I crystal form, a II crystal form, a III crystal form, a IV crystal form and a V crystal form of the compound as shown in formula (I) and a preparation method therefor. The new crystal form has a good stability, thereby making same better to use in clinical treatments.

##STR00001##